Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...

In a stark reflection of the challenges facing the tech sector, GCTK's stock has tumbled to a 52-week low, touching down at a mere $0.06, with a market capitalization shrinking to just $0.99 million.

GlucoTrack, Inc. (GCTK) is down by 24.56 percent during Tuesday trading despite announcing the successful completion of a ...

Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...

(RTTNews) - Glucotrack, Inc. (GCTK), a medical technology company focused on innovative diabetes solutions, on Tuesday announced the successful completion of its first in-human clinical study for ...

Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...

RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...